Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	5/24/2007 9:22:13 PM
	of 285

This clipping from 2 months ago makes me question the validity of today's BNN report. Cardiome Pharma "buy" Wednesday, March 21, 2007 1:49:51 AM ET Canaccord Adams NEW YORK, March 21 (newratings.com) - Analyst Karl Keegan of Canaccord Adams maintains his "buy" rating on Cardiome Pharma Corporation (ticker: CRME). The target price is set to C$21.40. In a research note published yesterday, the analyst mentions that the Phase 2a oral results are likely to be announced at the HRS 2007 in Denver. A Successful IV at the FDA and successful Phase 2b oral data are likely to generate an implied valuation of C$26.70 per share for Cardiome Pharma, the analyst says. The recent decline of about 15% in the company's share price offers an attractive investment opportunity, Canaccord Adams adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next